The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Scientific rationale<br />
Pierce Chow FRCSE PhD<br />
• Ablative therapy such as Y90 is efficacious in<br />
causing complete or partial destruction of tumour<br />
• HHowever new llesions i can arise i ffrom th the li liver or<br />
from metastasis – systemic molecular pathway<br />
ttargeted t dth therapy may preventt or dl delay thi this.<br />
• Y90 followed by an efficacious systemic therapy<br />
may confer improved outcomes in advanced HCC.<br />
• This hypothesis was tested in the AHCC05<br />
(<strong>SIRSA</strong>) trial of the Asia-Pacific HCC <strong>Trials</strong><br />
Group<br />
SGH – Surgery 8
Change language